Next Article in Journal
Involvement of Kynurenine Pathway in Hepatocellular Carcinoma
Next Article in Special Issue
Neurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistance
Previous Article in Journal
Fertility Sparing Treatment in Gastric-Type Endocervical Carcinoma
Previous Article in Special Issue
Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Erratum

Erratum: Rodriguez et al. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13, 3871

1
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
2
Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
3
Department of General Internal Medicine, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
4
University of Houston, Houston, TX 77004, USA
*
Author to whom correspondence should be addressed.
Cancers 2021, 13(20), 5178; https://doi.org/10.3390/cancers13205178
Submission received: 7 October 2021 / Accepted: 9 October 2021 / Published: 15 October 2021
(This article belongs to the Special Issue Involvement of the Substance P/Neurokinin-1 Receptor System in Cancer)
One contributor’s name was missing in the original version of the authorship of the paper [1]. This author is Zhongming Zhao, who should be listed as the third author. He belongs to the original affiliation 2 (Zhongming Zhao 2):
2 Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
The updated authorship is listed as below:
Emma Rodriguez, Guangsheng Pei, Zhongming Zhao, Sang T. Kim, Alexis German and Prema Robinson
The “Author Contributions” statement thus should be updated to the following version:
Author Contributions: Conceptualization, P.R.; methodology, P.R., E.R., S.T.K., G.P., and Z.Z.; formal analyses, P.R., S.T.K., G.P., and Z.Z.; investigation, A.G.; original draft preparation, P.R.; review and editing, P.R., E.R., S.T.K., and G.P. All authors have read and agreed to the published version of the manuscript.
The authors have confirmed that the updated authorship meets the ICMJE criteria, the guidelines of which are followed by this journal. We apologize for this error and state that the scientific conclusions are unaffected. The original article has been updated.

Reference

  1. Rodriguez, E.; Pei, G.; Zhao, Z.; Kim, S.T.; German, A.; Robinson, P. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13, 3871. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Rodriguez, E.; Pei, G.; Zhao, Z.; Kim, S.T.; German, A.; Robinson, P. Erratum: Rodriguez et al. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13, 3871. Cancers 2021, 13, 5178. https://doi.org/10.3390/cancers13205178

AMA Style

Rodriguez E, Pei G, Zhao Z, Kim ST, German A, Robinson P. Erratum: Rodriguez et al. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13, 3871. Cancers. 2021; 13(20):5178. https://doi.org/10.3390/cancers13205178

Chicago/Turabian Style

Rodriguez, Emma, Guangsheng Pei, Zhongming Zhao, Sang T. Kim, Alexis German, and Prema Robinson. 2021. "Erratum: Rodriguez et al. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13, 3871" Cancers 13, no. 20: 5178. https://doi.org/10.3390/cancers13205178

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop